MRMariana Gaspar Côrte Real

Mariana Gaspar Côrte Real

*This is an algorithmically generated author record based on publicly available information.

Latest Publications

  • Open Access

    DNA tumoral circulante na detecção da doença residual molecular e na predição de recidiva tumoral: avanços recentes e perspectivas clínicas.

    by Laysla Tamyres de Oliveira Borges, Paulo José de Andrade Lira Oliveira, Natália Maria Valeriano da Silva, Maria Clara Gomes Oliveira, Rafael Ramos Teles, Patrícia Cristina de Véras Souza Maia, Mariana Gaspar Côrte Real, João Eduardo Cordeiro Ferreira dos Santos, Victor Buarque Ribeiro de Siqueira, Milena Marcia da Silva

    Introduction: liquid biopsy, through the analysis of circulating tumor DNA (ctDNA), has become established in precision oncology as a tool to detect molecular residual disease and predict recurrence in solid tumors. Objective: to review recent advances in the use of ctDNA during follow-up after curative-intent treatment, highlighting clinical applications, therapeutic implications and current limitations. Methods: narrative literature review with a structured search strategy in PubMed/MEDLINE, SciELO and Google Scholar, using DeCS and MeSH descriptors combined with Boolean operators, covering 2021 to 2026; after screening of titles, abstracts and full texts, nine studies made up the final sample. Results: ctDNA detection after curative treatment identifies high-risk patients before radiological progression, with the most consistent evidence in colorectal cancer and promising results in breast cancer, non-small cell lung cancer and melanoma. Tumor-informed and tumor-agnostic approaches support risk stratification and individualized therapeutic decisions, including escalation and de-escalation of adjuvant therapy. However, analytical and clinical challenges remain, such as false-positive results caused by clonal hematopoiesis, reduced sensitivity at certain anatomical sites, lack of standardized protocols and high cost. Conclusion: ctDNA is a promising biomarker for the early detection of molecular residual disease and recurrence prediction, supporting personalized cancer care; nevertheless, its broad clinical adoption depends on further prospective validation, methodological standardization and cost reduction.